Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Melanoma 11Carcinoma, Renal Cell 8Lymphoma 7Neoplasm Metastasis 6Nasopharyngeal Carcinoma 6Lung Neoplasms 6Hematologic Neoplasms 5Glioblastoma 5Anus Neoplasms 5Rectal Neoplasms 4Prostatic Neoplasms 4Ovarian Neoplasms 4Multiple Myeloma 4Leukemia, Myeloid, Acute 4Hodgkin Disease 4Glioma 4Colorectal Neoplasms 4Carcinoma, Non-Small-Cell Lung 4Carcinoma, Basal Cell 4Uterine Cervical Neoplasms 3Urinary Bladder Neoplasms 3Thyroid Neoplasms 3Small Cell Lung Carcinoma 3Sarcoma, Kaposi 3Pancreatic Neoplasms 3Oropharyngeal Neoplasms 3Lymphoma, Large B-Cell, Diffuse 3HIV Infections 3Gliosarcoma 3Esophageal Neoplasms 3

Interventions

Vincristine 3Rituximab 3Prednisone 3Etoposide 3Doxorubicin 3Cyclophosphamide 3varlilumab 1prednylidene 1pomalidomide 1deltacortene 1Vorinostat 1Specimen Handling 1Nivolumab 1Magnetic Resonance Spectroscopy 1Immunoglobulin G 1Disulfides 1CT-P10 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Plasmablastic Lymphoma × Nivolumab × Clear all
NCT03038672 2026-05-12

Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas

National Cancer Institute (NCI)

Phase 2 Active not recruiting
54 enrolled 12 charts
Lymphoid

Plasmablastic Lymphoma, Burkitt Lymphoma, Lymphomatoid Granulomatosis, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Primary Effusion

Data powered by HemOnc (CC BY 4.0) Colophon âš¡